



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

November 6, 2013

Via E-mail

Ian Mortimer
Chief Financial Officer
Tekmira Pharmaceuticals Corporation
100-8900 Glenlyon Parkway
Burnaby, BC
Canada, V5J 5J8

Re: Tekmira Pharmaceuticals Corporation
Form 20-F for the Fiscal year Ended December 31, 2012
Filed March 27, 2013
File No. 001-34949

Dear Mr. Mortimer:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Jeffrey P. Riedler

Jeffrey P. Riedler
Assistant Director